PROCURVES+ / U-BODY BUST / 500COSMETICS BUST / ONTTOLABS BUST
Food supplement declared in France, declaration No 2019-6-429, decision dated 13 June 2019
PROCURVES+ / U-BODY BUST / 500COSMETICS BUST / ONTTOLABS BUST, from Natural Logistics S.L, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Foeniculum vulgare 200 mg per day, Trigonella foenum-graecum 200 mg per day, Pueraria montana 200 mg per day, Serenoa repens 200 mg per day, Piper nigrum 100 mg per day. 1 point in its composition requires a check (prohibited substance, dose or novel food). 4 rules of use apply to its ingredients (limits and warnings).
- Brand
- not provided
- Food business operator placing the product on the market
- Natural Logistics S.L
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Capsule
- Daily dose
- 2 comprimés par jour
- Directions for use
- prendre 2 comprimés par jour avec un repas
- Intended populations
- Women
- Not recommended (according to the manufacturer)
- Breastfeeding women, History of breast cancer, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year)
- Objectives stated by the manufacturer (these are not authorised claims)
- Antioxidant, Skin
Declaration 295997, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Foeniculum vulgare Mill. | Parties aériennes | Poudre (de plantes séchées ou broyées) | 200 mg |
| Trigonella foenum-graecum L. | Graine | Poudre (de plantes séchées ou broyées) | 200 mg |
| Pueraria montana var. lobata (Willd.) Sanjappa & Pradeep | Racine | Poudre (de plantes séchées ou broyées) | 200 mg |
| Serenoa repens (W.Bartram) Small | Fruit | Poudre (de plantes séchées ou broyées) | 200 mg |
| Piper nigrum L. | Fruit | Poudre (de plantes séchées ou broyées) | 100 mg |
| Humulus lupulus L. | Inflorescence | Poudre (de plantes séchées ou broyées) | 50 mg |
| Avena sativa L. | Graine | Poudre (de plantes séchées ou broyées) | 50 mg |
| Cnicus benedictus L. | Parties aériennes | Poudre (de plantes séchées ou broyées) | 50 mg |
Other active ingredients
| Name | Per day |
|---|---|
| Triglycérides à chaine moyenne | not declared |
Vitamins and minerals
Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).
| Declared form | Nutrient | EFSA limit, adults | Maximum dose in France |
|---|---|---|---|
| cupric sulphate | Copper | 5,000 µg | 2,000 µg |
| manganese sulphate | Manganese | 8 mg (safe level) | 3.5 mg |
| pyridoxine hydrochloride | Vitamin B6 | 12 mg | 2 mg |
Additives
E122, E460, E551, E171, E464, E463, E110, E341, E470b, E553b
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Label warnings
Le E110 et le E122 peuvent avoir des effets secondaires dans l'activité et l'attention des enfants. Les femmes ayant des antécédents personnels ou une patiente atteinte d'un cancer du sein ne doivent pas consommer ce produit. Ne pas prendre si vous êtes âgé de moins de 12 ans. Demander l'avis de votre médecin ou pharmacien.
Regulatory points
- À vérifier
The composition lists additive E171 (titanium dioxide), removed from the list of additives allowed in food, supplements included: since 7 August 2022, a supplement containing it can no longer be placed on the market in the Union. The declaration predates this removal: if the product is still sold, its formula must have changed; check the label.
Source: Regulation (EU) 2022/63: titanium dioxide (E171) removed from the food additives allowed in the EU, règlement (UE) 2022/63.
- Conditions légales
Foeniculum vulgare Mill.: La portion journalière recommandée ne doit pas conduire à une ingestion d'estragole supérieure à 0,05 mg/kg de poids corporel pour les enfants de moins de 12 ans.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Trigonella foenum-graecum L.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux femmes enceintes.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Pueraria montana var. lobata (Willd.) Sanjappa & Pradeep: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
- Conditions légales
Serenoa repens (W.Bartram) Small: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé ("Demander l'avis de votre médecin et /ou pharmacien").
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Foeniculum vulgare Mill.
Read the warning, when it applies and the studies cited
BITTER FENNEL- FOENICULUM VULGARE
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024, 2007).
Sources cited by Health Canada (2)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
- EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf
Condition of application: Essential oil and Tincture.
Ask a health care practitioner before use if you are taking any medications including birth control pills or hormone therapy or other health products (EMA 2007).
Sources cited by Health Canada (1)
- EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (EMA 2024, 2007).
Sources cited by Health Canada (2)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-vulgare-fructus_en.pdf
- EMA 2007. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller subs. vulgare var. vulgare oil. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 5 July 2007. [Accessed 2024 March 1]. Available from: http://www.e-lactancia.org/media/papers/Fennel-DS-EMEA2007.pdf
Health Canada monograph dated 29 November 2024
SWEET FENNEL -FOENICULUM VULGARE
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (EMA 2024).
Sources cited by Health Canada (1)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (EMA 2024).
Sources cited by Health Canada (1)
- EMA 2024. European Medicines Agency. Community Monograph on Foeniculum vulgare Miller. subsp. vulgare var. dulce (Mill.) Batt. & Trab., Fructus London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 31 January 2024. [Accessed 2024 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-foeniculum-vulgare-miller-subsp-vulgare-var-dulce-mill-batt-trab-fructus-revision-1_en.pdf
- Trigonella foenum-graecum L.
Read the warning, when it applies and the studies cited
FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010; Mills et al. 2006; Hoffman 2003; Blumenthal et al. 2000).
Sources cited by Health Canada (4)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
- Mills E, Duguoa J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation. An Evidence-Based Approach. New York (NY): Taylor and Francis; 2006.
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Health Canada monograph dated 29 May 2026
FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Topical
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
- Serenoa repens (W.Bartram) Small
Read the warning, when it applies and the studies cited
SAW PALMETTO – SERENOA REPENS
Route of administration: Oral
Cautions and warnings
Condition of application: All subpopulations.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: Adult males only.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to exclude a diagnosis of prostate cancer (USP-NF 2024; Mills and Bone 2005).
Sources cited by Health Canada (2)
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
- USP-NF 2024: United States Pharmacopeia and the National Formulary. Rockville (MD): The United States Pharmacopeial Convention, Inc.; 2024.
Condition of application: Adult females only.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking oral contraceptives or hormone replacement therapy (UpToDate 2024).
Sources cited by Health Canada (1)
- UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1
Contraindications
Condition of application: Adult females only.
Do not use if you are pregnant, breastfeeding, or attempting to conceive (UpToDate 2024).
Sources cited by Health Canada (1)
- UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1
- Humulus lupulus L.
Read the warning, when it applies and the studies cited
HOPS - HUMULUS LUPULUS
Route of administration: Oral
Cautions and warnings
Condition of application: Sleep aid.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if sleeplessness persists continuously for more than 4 weeks (chronic insomnia) (Berardi et al. 2002; Dipiro et al. 2002).
Sources cited by Health Canada (2)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: a pathophysiologic approach, 5th edition. New York (NY): The McGraw-Hill Companies, Inc.; 2002.
Condition of application: Other uses.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Barnes et al. 2007; Mills and Bone 2005; McGuffin et al. 1997).
Sources cited by Health Canada (4)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- Brinker F. Herb Contraindications and Drug interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
When using this product avoid taking with alcohol or products that cause drowsiness (Brinker 2010).
Sources cited by Health Canada (2)
- Brinker F. Herb Contraindications and Drug interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2014 : European Medicines Agency. Draft Community Herbal Monograph on Humulus lupulus L., Flos. London (UK): EMEA Committee on Herbal Medicinal Products (HMPC), 6 Mai 2014. [Consulté le 14 septembre 2023]. Disponible à : https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-humulus-lupulus-l-flos-revision-1_en.pdf
When using this product exercise caution if you drive or use machinery as this product may cause drowsiness (EMA 2014).
Sources cited by Health Canada (5)
- EMA 2014: European Medicines Agency. Draft Community Herbal Monograph on Humulus lupulus L., Flos. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 6 May 2014. [Accessed 2023 September 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-humulus-lupulus-l-flos-revision-1_en.pdf
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3e édition. London (UK): The Pharmaceutical Press; 2007.
- Brinker F. Herb Contraindications and Drug interactions, 4e édition. Sandy (OR): Eclectic Medical Publications; 2010.
- McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press; 1997.
- Cnicus benedictus L.
Read the warning, when it applies and the studies cited
BLESSED THISTLE - CNICUS BENEDICTUS - Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Contraindications
Do not use if you are pregnant (EMA 2023; Gardner and McGuffin 2013; Bradley 1992; Felter and Lloyd 1983).
Sources cited by Health Canada (4)
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (UK): British Herbal Medicine Association; 1992.
- EMA 2023: EMA/HMPC/32402/2022. European Union herbal monograph on Cnicus benedictus L., herba. London (GB): European Medicines Agency: Committee on Herbal Medicinal Products (HMPC); 2023 September 20. [Accessed 2025 December 23]. Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cnicus-benedictus-l-herba_en.pdf
- Felter HW, Lloyd JU. King's American Dispensatory, Volume 1, 18th edition. Sandy (OR): Eclectic Medical Publications; 1983 [Reprint of 1898 original].
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (EMA 2023; Brinker 2010; Blumenthal et al. 2000).
Sources cited by Health Canada (3)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- EMA 2023: EMA/HMPC/32402/2022. European Union herbal monograph on Cnicus benedictus L., herba. London (GB): European Medicines Agency: Committee on Herbal Medicinal Products (HMPC); 2023 September 20. [Accessed 2025 December 23]. Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-cnicus-benedictus-l-herba_en.pdf
Health Canada monograph dated 30 January 2026
BLESSED THISTLE - CNICUS BENEDICTUS - Topical
Cautions and warnings
For external use only.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Bradley 1992; Felter and Lloyd 1983).
Sources cited by Health Canada (3)
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (UK): British Herbal Medicine Association; 1992.
- Felter HW, Lloyd JU. King's American Dispensatory, Volume 1, 18th edition. Sandy (OR): Eclectic Medical Publications; 1983 [Reprint of 1898 original].
- Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
When using this product avoid contact with eyes. If contact occurs, rinse thoroughly with water.
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or last (for) more than 7 days.
Keep out of reach of children. If swallowed, call a poison control centre or get medical help right away.
Contraindications
Do not use on deep or puncture wounds, animal bites or serious burns.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Brinker 2010; Blumenthal et al. 2000).
Sources cited by Health Canada (2)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “PROCURVES+ / U-BODY BUST / 500COSMETICS BUST / ONTTOLABS BUST: composition and regulation”, https://compoatlas.com/en/supplements/products/295997-procurves-u-body-bust-500cosmetics-bust-onttolabs-bust, updated 15 November 2026.